Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage specialty biologics company with a portfolio of marketed and late-stage cell therapy products. The Company is engaged in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The Company markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant product for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), an autologous permanent skin replacement for the treatment of severe burns. It is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.